BICO Group AB Class B

BICO Group AB Class B

2.54
USD
+0.14
(+5.94%)
-0.63EPS
150.47MMarket Cap
Feb 17Next Earn

Q3 FY2026 · Earnings Call TranscriptNovember 11, 2026

Operator

Welcome to Bico Q3 2026 report presentation. For the first part of the presentation, participants will be in listen-only mode.

During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now, I will hand the conference over to the speakers CEO Anders Fogelberg, and CFO Eva Linsäter.

Please go ahead.

Anders Fogelberg

Good morning everyone, and welcome to Bico's earnings call for the third quarter of 2026. I'm Anders Fogelberg, President and CEO of Bico, and joining me today is our Group CFO, Eva Linsäter.

This is my first quarterly report since assuming the CEO role on September 1st, after joining Bico in mid-2024 as Chief Commercial Officer. Since September, I have spent a lot of time with our businesses, teams, and customers.

Those conversations have reinforced where Bico is strongest, but also where we need greater focus and discipline. I want to thank our employees, customers, and partners for their candid input, valuable insights, and continued trust in Bico.

Before we turn to the third-quarter results, I would like to introduce Bico 2030, our new strategy, which we are launching today. Eva will then cover the quarter, and I will close with our Q4 focus before the Q&A.

Let me start with the thinking behind Bico 2030. This is not about changing Bico's purpose or ambition.

Our vision remains the same: to enable life science labs to accelerate the discoveries that change lives. Bico 2030 is about being much clearer about where we can compete, where we can create the most value, and where we should allocate our resources.

To explain that, let me first take a step back and look at how we got here. Bico 2030 is the result of a three-step process during 2026.

In the spring, we carried out a comprehensive, customer-focused business review across all our businesses. Over the summer, it became the basis for updated commercial plans.

This autumn, together with our assessment of the large-scale lab automation project business, it came together in one group strategy. The review confirmed that many of Bico's strongest technologies, scientific capabilities, and customer relationships already sit within what we today define as precision biology.

We do not need to become a different company. We already have a strong foundation to build from.

It also drew on what we learned from executing our previous strategy, and one conclusion stands out: an attractive market and a competitive advantage in that market are not the same thing. We did not deliver on all the ambitions of Bico 2.0, particularly in scaling Biosero into the growth platform envisioned.

We underestimated what it takes to scale a large, customized project business built on third-party hardware in a market that became more competitive, capital-intensive, and disrupted by AI. The outcome is a strategy grounded in our portfolio, customer demand, and Bico's competitive edge, concentrating on our strongest positions.

Where are our strongest positions? In total, we serve three growing markets worth around $10 billion: 3D biology and biomaterials, $2.7 billion, growing at low double digits as research shifts from animal tests to human-relevant 3D models; cell imaging, isolation, and cell line development, $3.4 billion, growing at high single digits driven by new modalities such as monoclonal antibodies and cell and gene therapies; and automation of the wet lab, $4.1 billion, growing at mid to high single digits as AI moves the bottleneck from discovery and design to validation in the wet lab, and labs automate and miniaturize.

Within these markets, our current serviceable market is approximately $1.5 billion, growing at an estimated 4% to 7% annually. Behind these markets is a real problem worth solving.

Of around 18,500 recognized diseases, only about 4,000 have an FDA-approved treatment, that is about one in five. Drug development remains long, expensive, and complex: around $300 billion in annual R&D spend, 10 to 15 years to bring a drug to market, and $2.7 billion per approved drug including failures.

At the same time, science is moving quickly. Advanced cell models, automation, and AI are changing how researchers identify, test, and validate potential new therapies.

The challenge is increasingly about generating better biological data earlier and more efficiently. That is the problem precision biology addresses, and where we believe Bico can make a meaningful difference.

Bico comes into play early, in discovery and preclinical, the first three to five years and about a third of R&D spend. Only 1 in 13 candidates entering clinical trials is approved, and the costliest phase come late, with Phase 3 alone at more than a quarter of R&D spend.

At the same time, AI is transforming early drug discovery, accelerating target identification and the design of new molecules. As models generate candidates faster than ever, more of them need to be tested on living material, and that work still happens in the physical lab.

This makes the wet lab a critical bottleneck. An AI-designed candidate cannot progress forward toward a therapy until it has been tested and validated in living biology.

Without that step, much of the speed gained through AI upstream is lost. More reproducible workflows, higher quality data, and better human-relevant models can help identify weak candidates before late-stage costs and time accumulate.

Our precision biology instruments and offering are built for exactly this work, making them enablers of AI-driven drug discovery. At its core, Bico 2030 is about focus: to accelerate precision biology.

Bico is the precision biology company. Each of our brands brings a specific capability for handling living material precisely: the growth matrix, the conditions, the placement, and the analysis.

Our lead market is cell-based applications in biotech and pharma, where the need for precision is greatest. That is where we will concentrate our commercial resources, innovation, and capital, building on differentiated capabilities and established customer relationships.

The success of Bico 2030 will be measured by our ability to translate that focus into sustainable growth, improved profitability, and stronger cash generation. Across our businesses, we have differentiated capabilities in precision biology in three areas: handling, preparing, moving, and placing biological material with products like I.DOT and UP.SIGHT; culture, creating and maintaining the conditions biology needs with BIO X and our 3D matrices; and analysis, turning observations into evidence with CellCyte and our Rebel and Echo microscopes.

These are just a few examples. Automation, AI, and consumables run across all three.

Importantly, we do not need to build these from scratch. These capabilities exist in our products today.

How will Bico 2030 translate into value creation, and importantly, how should you expect to see progress over time? The strategy is built around three priorities.

First, precision biology at the core. We will concentrate resources on cell solutions and 3D cell models, where our competitive advantage is strongest.

Large-scale integrated lab automation projects will no longer be a core focus. We are assessing strategic options for Biosero to determine its best long-term path.

Importantly, we are not moving away from lab automation itself, but from large, highly customized integration projects built around third-party instruments and third-party automation hardware. The value-creation logic is straightforward: accelerate organic growth in our high-quality and in some cases world-leading instruments, increase the share of consumables, services, and software, and reduce our exposure to large, customized projects that have reduced profitability.

Second, customer-driven innovation enabled by AI. R&D will be more closely aligned with customer demand.

We will use AI in product development, make instruments ready for software agents and robots, and increasingly incorporate AI into the products themselves, complemented by selective bolt-on acquisitions. This should give us higher returns on R&D, faster development, and software revenue on our installed base.

Third, accountability close to the customer. Our business units will own growth, profitability, and execution, supported by a lean group function driving stronger commercial execution and operating leverage.

Together, these priorities are how we intend to achieve our financial targets. That brings me naturally to our financial ambitions.

First, three observations: past performance showed the group has not consistently reached its financial targets; what Biosero taught us, large-scale automation projects did not provide the leading, scalable platform we envisioned; and what the review confirmed, we already have businesses that drive growth and profitability. The strategic choice is to focus where Bico has the clearest competitive advantage and the strongest path to profitable growth.

Bico 2030 changes where we focus and how we execute, but it does not change our financial ambition. The board has reconfirmed our existing long-term financial targets: double-digit organic growth in constant currencies, an EBITDA margin less capitalized development costs about 10%, and net debt to EBITDA below three times.

New long-term financial targets will be defined once the current targets have been achieved. We are also strengthening our executive management to increase business accountability and bring decision-making closer to our customers.

As of today, Eva and I will be joined by three new members: Julian Riba joins as Chief Technology Officer, bringing deep experience in developing and bringing life science instruments to market, with a strong focus on advancing our AI capabilities across products and R&D; Petros Apostolopoulos joins as Managing Director of Lab Instruments, with a particular focus on businesses including Dispendix, CYTENA, and Echo, as well as the strategic development of our broader offering; Abhi Minocha joins as Managing Director of CELLINK, bringing extensive commercial and operational experience from across the group. Together, these changes bring business leadership closer to group decision-making and strengthen the connection between customers, commercial priorities, and technology development.

At the same time, Katarina Nordlund and Jesper Haglund will continue in their current roles and as members of our extended leadership team, but will leave the executive management. Strategy ultimately comes down to execution, and execution depends on culture.

For us, that culture will be built around three values: ownership means clear accountability for our actions, decisions, and results, and following through on our commitments; innovation means curiosity and the courage to explore new ideas, embracing technology and new ways of working to keep finding better ways forward; and impact means the difference our work makes, helping our customers succeed, and contributing to discoveries and therapies that can change lives. Ownership, innovation, impact: this is the culture we are building, and how we will execute Bico 2030.

Today, I have deliberately focused on the high-level strategic direction. On November 25th, we will host a dedicated Strategy Deep Dive, where we will go further into Bico 2030 and how we intend to execute this strategy.

You can register at bico.com/investors. Today is also about our Q3 interim report.

I will now hand over to Eva Linsäter to take you through our third quarter financial performance.

Eva Linsäter

Thank you, Anders. I will now take you through the group's financial performance for the third quarter in 2026.

Unless otherwise stated, all figures in this section are in Swedish kronor and refer to continued operations. Let me begin with a few key figures from the quarter.

Net sales came in at 465 million, that is an increase of 20% quarter-over-quarter and 19% organically. Q3 is a strong quarter, but the most important message is not the growth rate.

It is that our core benchtop business continued to grow while our cost base is coming down. Excluding the large-scale integrated automation project business, instrument sales grew 14% and our consumables grew 5%.

Adjusted EBITDA was 124 million, giving us an adjusted EBITDA margin of 27%. On working capital, we ended the quarter at 50% of rolling 12 months sales.

Cash flow from operating activities was -41 million, mainly due to movements in working capital. Sales grew by 20% and by 19% organically.

In Q3, SCIENION signed extended supply and license agreements with a diagnostic customer, prolonging an existing collaboration. The agreement contributed 135 million in revenue during the quarter.

On this, 83 million related to license revenue for the five-year non-cancelable period, recognized at a point in time. The agreements are estimated to have a combined contractual value of approximately €50 million over a 10-year term.

Our Q2 report disclosed €3.9 million in revenue related to earlier periods and €10.6 million in total license revenue. Of the €10.6 million, €2.9 million were related to earlier periods, and was, therefore, also included in the €3.9 million.

While the license income is recognized upfront under IFRS, the cash is received over the contractual term. This creates a timing difference between earnings and cash flow.

Excluding the supply and license agreements, sales declined, with instrument sales down 11% in the quarter. The prior-year quarter was unusually strong, reflecting a new large-scale integrated automation project launched during that period, with high initial traded third-party instruments.

Our own Bico benchtop instruments, however, continued to perform well, with sales up 14%. Consumables sales also grew by 5%.

North America remained our most important market and accounted for just over 70%, even if it was boosted this quarter with the revenue related to the SCIENION supply and license agreement. We see improved gross profit mainly due to the SCIENION agreements, but also excluding this effect, gross profit was stronger compared to the same quarter last year, generated from continued favorable product mix and outsourced production.

Turning to our profitability, adjusted EBITDA was 124 million with a margin of 27%. The reported profitability is exceptionally strong and includes a significant contribution from the SCIENION agreements.

We, therefore, don't view the Q3 margin as a representative of a normal quarterly run rate. What gives us confidence is the combination of underlying growth in benchtop instruments and an improved cost discipline.

Sales and administration expenses were lower than a year ago, reflecting actions taken in previous quarters and our continued focus on cost discipline and operational efficiency. Personnel costs and external services have come down, both high cost drivers for the group.

After the quarter end, we completed the integration of Cellenion into SCIENION, which is the main part of the initiated restructuring program from Q1, which is expected to generate around 30 million in annual savings. Before turning to cash flow, I will address the Biosero impairment, which follows from the strategic assessment Anders outlined earlier.

In our Q2 report, we said we were assessing our position in the large-scale integrated lab automation project business. That review is now complete, and its conclusion is clearer and harder than our earlier commentary suggested.

Biosero has not developed as expected. Sales and order intake have declined, and the larger legacy projects proved less profitable than anticipated as they were completed.

The market is also changing. AI tools are reshaping laboratory automation, and major players are committing substantial capital and resources with own robotics hardware as requirements for market leadership.

Following the assessment, we recognize an impairment of approximately 296 million against Biosero's remaining goodwill and technology. This is a non-cash charge with no effect on liquidity or covenants.

We continue to see value in Biosero and are assessing options to determine its ideal long-term potential. We remain fully committed to its customers throughout this process.

Cash flow from operating activities was -41 million, mainly reflecting working capital movements. We saw an increase in operating receivables of 85 million, mainly related to the extended supply and license agreements entered into during the quarter.

The revenue from these agreements were recognized at a point in time, while the related cash payments are received over the contract term. At the same time, we saw a decrease in operating liabilities with a negative cash flow impact of almost the same amount, 81 million.

This includes a negative 10 million from lower accounts payable, and a negative 45 million from the decline in long-term projects. We ended the quarter with cash equivalents of 555 million and a net cash position of 124 million.

At quarter end, net working capital was approximately 50% of rolling 12 months sales. This is the highest working capital in several years and has three main drivers: first, at Biosero, working capital increased as we completed existing large-scale projects while taking on fewer new ones; second, SCIENION's accounts receivable and other receivables increased during the quarter linked to the recorded supply and license agreements; third, accounts payable declined further, also increasing net working capital.

Together, these movements weighed on cash conversion in the quarter. Now, over to you, Anders.

Anders Fogelberg

Let me finish with our priorities for the remainder of the year. With Bico 2030 as our strategic direction, the focus now shifts to execution.

First, our Strategy Deep Dive on November 25th. We will also anchor the strategy internally with a clear commercial and operational priority list for each business unit.

We will continue to assess options for Biosero to determine its ideal long-term potential, while remaining fully committed to its customers, as Eva just said. We will strengthen the group's capabilities within AI and ramp up for key product launches in 2027.

Throughout this, we will maintain strong discipline on costs, cash generation, and capital allocation. Ultimately, Bico 2030 will not be judged by today's announcements.

It will be judged by our ability to deliver stronger commercial performance, improved profitability, and cash generation quarter after quarter. As I mentioned, we will go deeper into Bico 2030 at our Strategy Deep Dive on November 25th.

That presentation starts at 9:00 a.m. Central European Time.

You can register at bico.com/investors, and we hope you will join us. Let me close by coming back to our three corporate values: ownership, innovation, impact.

That is the mindset we are bringing to Bico 2030, and to our vision to enable life science labs to accelerate the discoveries that change lives. Once again, thank you to our employees, customers, and partners for the candid discussions, valuable insights, and continued trust in Bico.

The direction is clear. Now it is about execution and delivery.

With that, Eva and I are ready to take your questions.

Operator

If you wish to ask a question, please dial pound key 5 on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key 6 on your telephone keypad.

The next question comes from Maria Carlsson Assapeva from DNB Carnegie. Please go ahead.

Maria Carlsson Assapeva

Hi, Anders. Hi, Eva.

Thank you for taking my question. I wanted to start on the instruments there.

You did highlight in the report and now in the presentation that own instruments are remaining strong year-over-year, and the comparable quarter was especially strong as well. Could you elaborate a bit more on that?

Also, what should we expect to see going forward? Maybe talk a little bit about what we see developing into Q4.

Thank you.

Anders Fogelberg

Absolutely. We're very happy with the instrument sales in quarter three.

We saw a strong momentum. We see some coming back in the academic segment.

We see a good progress in diagnostics, pharma, biotech. We believe that the AI revolution happening right now is very well-positioned for our instruments.

The demand for wet lab services and the capabilities that we have is well-positioned. The comparison quarter last year, 2025 in Q3, we had a big project start with Biosero that we also announced in a press release.

We had a very strong instrument sales that quarter as a reference. The Biosero products were traded by third parties.

If we remove that Biosero impact from both quarters, and if you also remove the SCIENION one-time effect and just look at our instruments, 14% was a strong results. We don't give forecast, but I can say that the purpose of the new strategy is to give us the best conditions possible to consistently reach our financial targets.

Maria Carlsson Assapeva

All right, thank you. A little bit more on general market conditions.

We've heard generally in life science tools and so on that there's been gradually improving market conditions, particularly in pharma, biotech. You mentioned in the report that you continue to see weak academia demand, and then there's some tariff-related pressure, and so on.

Could you please help us understand the trends a bit more? What do you see out there?

What do you think needs to change in order for you to achieve this double-digit growth target that you have now? Or that you had also before?

Anders Fogelberg

To achieve our financial targets, we launched the new strategy Bico 2030, which gives us the best conditions. If we look at the market right now, yes, we have seen over the last few months that pharma, biotech has been a bit stronger, and diagnostics has done okay as well.

We see still the academic segment struggle. I think we said in the last quarter that we see NIH funding is coming back, but it's favoring bigger projects, which in turn is favoring more specialized equipment where we are being favored with some of our assortments.

We also see fewer project starts by the new way that NIH operates in the US, which means that some of our products that are slightly more into the commodity field, they don't have as good as a market as we saw in the past before the NIH changes started. Academic segment is still a segment that we follow closely, and it's an important segment for us, but we see some headwind there still.

Maria Carlsson Assapeva

All right, thank you. I'll get back into the queue.

Operator

As a reminder, if you wish to ask a question, please dial pound key 5 on your telephone keypad. The next question comes from Ludvig Lundgren from Arctic.

Please go ahead.

Ludvig Lundgren

Yes, hi guys, and thank you for taking my questions. First off, I wanted to start off with a bit of a follow-up to that last question.

Thinking about point-in-time sales in Q4 last year, which I believe excludes the Biosero business, it was a very strong number in a quite challenging market. With funding, I guess, improving now on the pharma and biotech side, how do you view the potential to deliver similar point-in-time sales in Q4 this year?

Anders Fogelberg

We don't give forecast at Bico, and we are happy with our Q3 results. We see a strengthening of demand in a few segments that struggled a year ago with the tariffs and the uncertainties, also the geopolitical tensions.

When we talk with customers, when we visit events, we sense that things are normalizing a bit, and I think that's what we hear from the other players in this industry. Regarding Q4, I cannot say anything relating to future quarter.

Ludvig Lundgren

Fair enough. Thanks.

Then so in Q3 here you had a very significant effect from the license and supply agreement. Is it possible to share the margins, thinking mainly here about the gross margin adjusting for the effect from this agreement?

Eva Linsäter

We don't give exact numbers, but what we can say and what we said in the call is that if you take out the supply and license agreements, we still see an improved gross profit margin, which comes from product mix, but also from certain outsourcing of instrument production.

Ludvig Lundgren

Then you mean improved year-over-year or

Eva Linsäter

Yes, compared to the same quarter last year, sorry.

Ludvig Lundgren

Thanks. Then I also wanted to ask on the opex side, which came in at least below what I had expected in general.

I believe you expect to have the full effect from this cost cuts and restructuring you have done in Q4, but yeah, maybe if you can elaborate a bit on how much of these effects we're already seeing here in Q3.

Eva Linsäter

You can see that we have had improvements during the quarters for this year, and we launched the restructuring program in Q1, but we also did restructuring in 2025. We can see that the Q1 restructuring is coming out as expected.

Of course we see some effects of that in Q3, as we said earlier, and we will see the full effect later in Q4.

Ludvig Lundgren

Okay. Great.

Those were my questions. I'll jump back into the queue.

Eva Linsäter

Thank you.

Operator

There are no more questions at this time. I hand the conference back to the speakers for any closing comments.

Anders Fogelberg

Thank you for your questions and for joining us today.

Operator

The next question comes from Gustaf Laudon Meyer from Redeye. Please go ahead.

Gustaf Laudon Meyer

Hi, everyone. Thank you for taking my questions as well.

Most of my questions have already been answered, but just a couple of add-ons. Maybe you talked about the gross margin before, but maybe you can elaborate a bit more on how do you expect it to develop now when the mix shifts away from these larger projects?

Eva Linsäter

We can see that we have a strong growth in benchtop instrument sales, and we have a product mix that is positive in this quarter. How it looks, we expect the margin to be around the same level, but we don't give any forecast in Q4 how we see the gross profit margin evolving.

Gustaf Laudon Meyer

Thank you. Also, you talked a little bit about it in your presentation about the R&D priorities.

Maybe you could add some more colors to that of the priorities will change with the new strategy.

Anders Fogelberg

Absolutely. The core of the new strategy is precision biology, and the products and solutions that support that for our customers.

We are looking at their portfolios of the German instrument companies, CELLINK in Sweden, Echo of course in the US, and ABM. What we're looking at is to add functionality to current portfolio, that is adding AI, which we saw recently with a few of our microscopes and our UP.SIGHT from CYTENA.

We are looking at adding AI functionality. We are looking at adding new functions to them.

We are also looking, of course, into next-generation products, hardware, software. We have some great initiatives going on.

We don't talk very openly about exactly how our pipeline of products look like, but we have initiatives that we strongly believe in that will serve our customers in this new focus area of precision biology.

Gustaf Laudon Meyer

Perfect. Thank you very much.

I will go back to the queue. Thanks.

Operator

There are no more questions at this time. I hand the conference back to the speakers for any closing comments.

Anders Fogelberg

Thank you all for questions, and for joining us today. We look forward to seeing many of you at our upcoming Strategy Deep Dive later in November.

Thank you again, and have a great Wednesday.